When every corner sells the same vial, what's left to compare?
In a market this crowded, speed and convenience have already been optimized to the floor. Half a dozen operations around downtown will get medication into your hands this week. So the differentiating questions move upstream. Who examined you? Who checked the labs that say this medication is safe for your kidneys, your thyroid history, your pancreas? Who is on the hook when week four brings vomiting that won't stop, and what are they going to do about it?
Those questions are the entire reason our program exists in family medicine rather than retail wellness. We aren't the fastest option in Pinellas County and won't pretend to be. We're built for the person who has watched the market mature enough to ask what happens after the first injection.
Saturation cuts one way in our favor, though: a St. Pete patient shopping this category in 2026 is unusually well informed. You've probably compared a few offers already, from the storefronts near Central Avenue to the brands renting space in your podcast feed, and noticed how little any of them say about labs, exclusions, or year two. Skepticism like that is the right instinct. Bring it to the consult; it holds up well here.
What physician monitoring means, month to month
The phrase gets used loosely, so here's what it means in this practice. Your dose titration runs on a follow-up cadence set by your prescriber, not by a refill timer. Side effects get managed by the physician who knows your chart: the first eight weeks are typically the roughest stretch, GI symptoms are common, and adjustments in that window are frequently what separates patients who stay on therapy from patients who quit. Labs get rechecked when the clinical picture calls for it. And everything lives in a medical record that connects to the rest of your care, so the next doctor who treats you can see what happened here.
Monitoring is also where honesty lives. Some patients respond strongly, some modestly, some barely at all, and we track which one is happening instead of letting a subscription auto-renew past the point of usefulness. Nobody can promise how your body will respond to these medications, whatever the signage on 4th Street implies, and a program that monitors is a program that can tell you the truth when the answer is "this isn't working."
Sketch the arc and the value gets concrete. Early months usually mean closer contact while the dose climbs and the GI symptoms peak and settle. The middle stretch is where plateaus surface, where a dose decision or a lifestyle adjustment does more than willpower ever did, and where a prescriber who has watched your labs move can distinguish a stall from a stop. Later, the conversation turns to maintenance: what dose sustains the result, what the plan looks like if you ever discontinue, and how the regain data, which is sobering, shapes both answers. None of those stages runs on a refill timer. All of them run on a chart.
We turn people away, and that's a feature
An evaluation that can't end in "no" isn't an evaluation. Before prescribing we screen for the exclusions that matter: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe gastroparesis, prior pancreatitis, an active eating disorder, and pregnancy or planned pregnancy. We also hunt for the conditions that masquerade as simple weight gain or complicate treatment: sleep apnea, mood disorders, and current medications that push weight up.
When something disqualifying or concerning surfaces, you hear about it directly, along with what we'd do instead. That might be treating the underlying condition first, choosing a different therapy, or coordinating with a specialist. What you won't get is a prescription issued around a red flag because the business model needed the sale.
The evaluation and the lab panel
The initial visit is in person and runs a full 45 minutes. It covers your weight history and its turning points, prior attempts and what came of them, sleep, stress, activity, eating patterns, a full medication review, and a focused exam. Then labs: HbA1c and fasting glucose for prediabetes and type 2 diabetes, a comprehensive metabolic panel for kidney and liver function, a lipid panel for cardiovascular risk, TSH because thyroid disease is a common hidden driver of weight change, plus any additional markers your history earns.
Candidacy follows FDA labeling for the weight management brands: generally adults with BMI 30 or higher, or 27 and higher with at least one weight-related condition. If you clear the workup, the options talk covers branded versus compounded, semaglutide versus tirzepatide, coverage realities, and self-pay, with the trade-offs and FDA-approval status of each option laid out plainly.
Insurance and fees, settled before anything is prescribed
In-network today: Aetna, ChampVA, and UnitedHealthcare, through Dr. Saylor. We verify benefits before any prescription decision, because medication coverage depends on your plan and your indication, and weight management indications are the ones plans most often restrict or exclude. Prefer to keep insurance out of it? Self-pay is available, with the rate depending on visit type, medication bundling, and labs ordered. Exact figures come from the billing team at (813) 670-3331 before you commit to anything, never after.
Prior authorization, and why the workup helps you win it
A wrinkle worth knowing before you start: for weight management indications, many plans that do cover these medications still require prior authorization, meaning the insurer wants clinical justification before it pays. This is another place the med-spa model quietly fails its customers, because a five-minute consult generates nothing an insurer will accept. A family medicine workup generates exactly what the process asks for: documented BMI and history, lab results, weight-related conditions on the chart, and a prescriber of record who can answer the payer's questions. We can't promise any plan's answer, and coverage for a type 2 diabetes indication generally runs smoother than for weight management alone, but arriving with a complete clinical file beats arriving with a receipt. Benefits verification happens before your prescription decision either way, so you'll know where you stand up front.
What each number actually changes about your plan
A lab panel is only worth drawing if the results are capable of changing something. Storefront programs sometimes order bloodwork and then prescribe the same thing regardless, which is theater with a needle attached. Here is what each measure is for, in the sense of what decision it moves.
HbA1c does the most work. In the 5.7 to 6.4 percent band it establishes prediabetes, which reframes the whole effort as prevention and raises the priority of starting. At 6.5 or above it establishes diabetes, which changes the clinical target, changes how glucose is monitored during titration, and materially changes how a payer reads the request. Creatinine and estimated filtration from the metabolic panel set how closely kidney function is watched, and a low or falling value is a specific reason to slow a dose step, since the dehydration that comes with vomiting and poor intake hits the kidneys first. Liver enzymes serve two purposes at once: they screen for the fatty liver disease that so often accompanies this weight, and they establish the baseline that makes any later change interpretable rather than alarming.
TSH decides whether an untreated thyroid is part of the story, and an abnormal result frequently changes the sequence rather than the destination, because correcting thyroid function first can alter what the weight does before anything else is added. The lipid panel sets the cardiovascular context that the entire treatment is ultimately aimed at, and it gives you a second scoreboard, which matters on the months the scale refuses to move. Calcium and electrolytes flag the metabolic problems that would otherwise be discovered the hard way. And your medication list, which is not a lab but belongs in this list, routinely changes the plan more than any single value on the panel does.
What follows from all of it is a decision with reasons attached: treat, treat but monitor a specific value more closely, treat something else first, or refer. Repeat draws later go to a Quest or LabCorp near your home or office rather than back to the practice, and established St. Petersburg patients review those results on Florida telehealth with the physician who ordered them.
St. Petersburg ZIPs & nearby areas we serve
- St. Petersburg core: 33701-33707 (downtown, Old Northeast, Snell Isle, Allendale, Bartlett Park, Greater Pinellas Point)
- Clearwater: 33755-33763 - see GLP-1 in Clearwater
- Tampa proper: - see GLP-1 in Tampa
The prescriber behind the program
Dr. Jason Saylor, DO is a board-certified osteopathic family medicine physician with 17 years of clinical experience, serving as Chief Medical Officer at Ascend. His scope explicitly includes weight loss management, chronic disease management (diabetes, hypertension, hyperlipidemia, thyroid disease), and preventive medicine. St. Petersburg-area patients see him in person at our offices and via Florida-statewide telehealth.
Related metabolic problems we manage in the same chart
Weight is usually one thread of a metabolic story, and this program sits inside our medical weight loss pillar so the whole story gets managed together. Type 2 diabetes with weight goals often lets a single medication serve both indications. Hypertension tied to weight gets coordinated medication review and lifestyle work rather than a second, disconnected prescriber. Dyslipidemia and metabolic syndrome frequently improve as weight comes down, and prediabetes in the HbA1c 5.7 to 6.4 percent range is exactly where intervention can still prevent progression. Fatty liver disease (MASLD) treats primarily through weight loss. Preventive screenings continue throughout, because the underlying goal is cardiovascular risk reduction, not a before-and-after photo.
FAQs about GLP-1 weight loss in St. Petersburg
What is prior authorization, and who handles it?
It is your plan requiring documented clinical justification before it will cover a medication, and it is our job rather than yours. Weight management indications trigger it far more often than not. We start the paperwork before anything is prescribed, so the answer arrives before the pharmacy counter delivers a surprise.
Why does a full workup help an authorization succeed?
Because an authorization is a documentation exercise, and a workup is documentation. A panel showing where your HbA1c, lipids, and metabolic markers actually sit, attached to a recorded history and a physician's assessment, is the material a reviewer is asking for. A questionnaire produces nothing to submit.
What happens if the plan denies coverage anyway?
You get told directly, along with what the denial was based on and whether an appeal has a realistic basis. Some denials are worth appealing with additional clinical documentation and some are not, and we will say which one yours looks like rather than filing paperwork indefinitely.
Does a diabetes diagnosis change the coverage picture?
Substantially. Plans generally treat a type 2 diabetes indication more favorably than a weight management one, which is part of why the panel matters: it establishes what you are actually being treated for. See our type 2 diabetes overview for how the two are managed together.
Which plans is Dr. Saylor in network with?
Currently Aetna, ChampVA, and UnitedHealthcare. Whether your plan covers the medication itself is a separate question from whether it covers the visit, and both get verified before a prescription decision. If your plan is not on that list, the clinical program is unchanged and only the payment conversation differs.
Which lab result would actually change what you prescribe?
Several of them. An HbA1c at or above 6.5 percent establishes diabetes and changes the target, the monitoring, and how a payer reads the request. A low or falling kidney filtration value is a specific reason to slow a dose step. Liver enzymes can redirect attention to fatty liver disease. An abnormal TSH can change the sequence entirely, because correcting thyroid function first sometimes changes what the weight does on its own. If a panel could not change any of that, there would be no reason to draw it.
Can I be seen with no insurance at all?
Yes. Self-pay is available and the specifics depend on visit type, whether medication bundling is involved, and which labs are ordered. Our medical billing team confirms your exact situation when you call (813) 670-3331, and that conversation happens before anything is prescribed.
Is a compounded preparation the fallback if coverage fails?
It is not framed that way here. A compounded preparation is used when your physician documents an individual medical need for one, and that determination is clinical rather than administrative. Compounded semaglutide and tirzepatide are not FDA-approved, which is a fact you are entitled to hear before a coverage outcome pushes any decision.
Compounded semaglutide and tirzepatide, prepared by a licensed pharmacy when there is a documented individual medical need, are not FDA-approved. Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose titration. Serious risks include pancreatitis, gallbladder disease, and possible worsening of certain conditions. Weight loss results vary substantially. This page is informational and does not substitute for a clinical visit. See FDA prescribing information for semaglutide and tirzepatide products, available via FDA Drugs@FDA.